Cervical cancer
Conditions
Interventions
cervical cancer >= Stage III:DC cell therapy
Sponsors
People's Hospital of Xinjiang Uygur Autonomous Region
Eligibility
Sex/Gender
Female
Age
47 Years to 77 Years
Inclusion criteria
Inclusion criteria: 1. Patients with cervical cancer confirmed by histopathology and / or cytology. 2. The subjects were patients with advanced cervical cancer (= IIIB). 3. HPV16 positive patients in cervical cancer. 4. Patients with cervical cancer who are ineffective in regular treatment or lack of effective treatment, and may benefit after being included in the clinical trial. 5. The heart, lung, liver and kidney functions were normal in patients without severe hematopoietic dysfunction. 6. Subjects with performance status (PS) ECoG 0 to 1 or Karnofsky score > 70. 7. The persistent effect of previous anti-tumor treatment (radiotherapy, chemotherapy) should be excluded. The time interval between the treatment and previous treatment should be enough, usually at least 4 weeks, to avoid the interference of previous treatment. 8. Subjects with life expectancy of at least 6 months can be followed up effectively. 9. Subjects aged 18-65. 10. The subjects with complete medical records in the past agreed to keep the medical records before and after the trial for efficacy comparison, and signed the informed consent.
Exclusion criteria
Exclusion criteria: 1. Subjects who have received relevant treatment and taken drugs in recent 4 weeks; 2. Patients with serious cardiovascular, liver, kidney, blood system, hyperthyroidism, coronary atherosclerotic heart disease, hypertension or pheochromocytoma, neurasthenia and other serious primary diseases and mental diseases; 3. Patients with history of chronic liver disease or hematological diseases in the past; 4. Patients who are participating in other clinical trials or have participated in other clinical trials in the past month; 5. Subjects with suspected or true history of alcohol or drug abuse, or other pathological changes or conditions that reduce or complicate the possibility of enrollment according to the judgment of researchers, such as frequent changes in working environment, unstable living environment, etc., which are likely to cause loss of follow-up; 6. For patients with incomplete medical records or unable to provide examination report after the completion of the trial, their data are not complete enough to compare the effect before and after the treatment. 7. Other patients identified by the researchers as unsuitable for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HPV viral loads;tumor marker SCC;Colposcope;MRI/CT scanning;Blood routine; | — |
Countries
China
Contacts
Public ContactMayinuer·Niyazi
People's Hospital of Xinjiang Uygur Autonomous Region
Outcome results
None listed